Zobrazeno 1 - 10
of 26
pro vyhledávání: '"M. J. Casanova"'
Autor:
M Baldan-Martin, M Azkargorta, I Lloro, I Soleto Fernández, M Orejudo, C Ramírez, S García, J Mercado, S Riestra, M Rivero, A Gutiérrez, I Rodríguez-Lago, L Fernández-Salazar, D Ceballos, J M Benítez, M Aguas, I Bastón-Rey, F Bermejo, M J Casanova, R Lorente, Y Ber, V Royo, M Esteve, F Elortza, J P Gisbert, M Chaparro
Publikováno v:
Journal of Crohn's and Colitis. 17:i268-i271
Background Inflammatory bowel diseases (IBD) are chronic, heterogeneous, and inflammatory conditions mainly affecting the gastrointestinal tract. Currently, endoscopy is the gold standard test for assessing mucosal activity and healing in clinical pr
Autor:
M Baldan-Martin, C Rubín de Célix, M Orejudo, L Ortega, S Fernández-Tomé, I Soleto, C Ramírez, R Arroyo, P Fernández, C Santander, J A Moreno-Monteagudo, M J Casanova, F Casals, S Casabona, I Becerro, U M Marigorta, A M Aransay, D Bernardo, M Chaparro, J P Gisbert
Publikováno v:
Journal of Crohn's and Colitis. 17:i210-i212
Background In recent years, evidence shows that long non-coding RNAs (lncRNAs) are key regulators of gene transcription and play important roles in the pathogenesis of inflammatory bowel diseases. LncRNA are involved in regulation of intestinal epith
Autor:
C Rubín De Célix, J Martín de Carpi, G Pujol, L Palomino, M Velasco, R Martín-Masot, V M Navas-López, E Ricart, M J Casanova, A Rodríguez Martínez, E Leo, A Alcaraz, M Mañosa, V Hernández, R Fernández, C Sánchez, L Menchén, F Mesonero, M Barreiro-De Acosta, N Martinon, C Tejido Sandoval, A Rendo Vázquez, P Corsino, R Vicente, A Hernández-Camba, J R Alberto Alonso, I Alonso-Abreu, A M Castro Millán, L Peries Reverter, B Castro, E Fernández-Salgado, M M Busto Cuiñas, J M Benítez, L Madero, F Clemente, S Riestra, S Jiménez-Treviño, M Boscá, M Chaparro, J P Gisbert
Publikováno v:
Journal of Crohn's and Colitis. 17:i37-i39
Background It has been suggested that the transition of patients from paediatric to adult care units may be key in the outcomes of inflammatory bowel disease (IBD). However, the impact of transition in real clinical practice has been barely studied.
Autor:
I Soleto, M Baldan, C Ramírez, M Orejudo, S García, J Mercado, M Azkargorta, I Lloro, L Ortega Moreno, L Aldars Garcia, S Riestra, M Rivero, A Gutiérrez, I Rodríguez-Lago, L Fernández, D Ceballos, J M Benítez, M Aguas, I Bastón Rey, F Bermejo, M J Casanova, R Lorente, Y Ber, D Ginard, M Esteve, F Elortza, J P Gisbert, N Martin-Cofreces, M Chaparro
Publikováno v:
Journal of Crohn's and Colitis. 17:i217-i219
Background The etiology and pathogenesis of inflammatory bowel disease (IBD), Crohn's disease (CD), and ulcerative colitis (UC) are complex and the mechanisms that lead to the development of these diseases remain unclear. Extracellular vesicles (EVs)
Autor:
A López García, J M Benítez, C Maroto-Martín, S J Fernández-Prada, V Marquina, G E Rodríguez, F Mesonero, A J Lucendo, P Flórez-Díez, M J Casanova, N García-Morales, J Miranda, M Vicuña, G Font, C Suárez-Ferrer, L Bernal, L Peries, A Mínguez, J Tejedor, P Pérez-Galindo, A Elosua, E A Lastiri, E Brunet, J Llaó, I Rodríguez-Lago, R Ferreiro-Iglesias, L López, I González, S P Ortega, S Monsalve, L Márquez-Mosquera, M González-Vivó, F Murciano, Y Zabana, M Barreiro-de Acosta
Publikováno v:
Journal of Crohn's and Colitis. 17:i465-i467
Background There is scarce information about Crohn’s disease (CD) affecting oesophagus, stomach and duodenum. The aim of the study was to describe phenotypic features, disease course and treatment response in these patients. Methods Patients with C
Autor:
M Chaparro, M García Donday, S Rubio, C Calviño Suarez, A Nuñez Ortiz, M Figueira, S Marín Pedrosa, M Rivero, A Fernández-Clotet, L Madero, M T Diz-Lois Palomares, I Pérez-Martínez, A Ruiz-Cerulla, M Arroyo, M Piqueras, C Suarez Ferrer, M Aguas, M Calvo Moya, I Guerra, P López Serrano, J M Vázquez Morón, L Arias García, M J Casanova, J M Huguet, G Valldosera Gomis, B Zúñiga de Mora-Figueroa, R Armesto, P Martínez Montiel, I Rodríguez-Lago, P Sendra Rumbeu, R Camargo Camero, D Hervías Cruz, G Molina Arriero, M Barreiro-de Acosta, D Acosta, Y Brenes, S Hermida, P Parra, A Garre, J P Gisbert
Publikováno v:
Journal of Crohn's and Colitis. 17:i874-i876
Background Biological drugs used for IBD are detected in breast milk at a concentration below 10% of the maternal serum concentration and have therefore been considered as permitted drugs. However, warnings have recently been published regarding vacc
Autor:
M Baldan-Martin, I Lloro, M Azkargorta, C Ramírez, I Soleto Fernández, M Orejudo, S García, J Mercado, C H Gordillo, S Riestra, M Rivero, A Gutiérrez, I Rodríguez-Lago, L Fernández-Salazar, D Ceballos, J M Benítez, M Aguas, I Bastón-Rey, F Bermejo, M J Casanova, R Lorente, Y Ber, V Royo, M Esteve, F Elortza, J P Gisbert, M Chaparro
Publikováno v:
Journal of Crohn's and Colitis. 17:i202-i204
Background Inflammatory bowel disease (IBD) is a complex multi-factorial disease characterized by chronic inflammation of the gastrointestinal tract. Despite significant efforts to understand the pathogenetic mechanisms of IBD, the elucidation of its
Autor:
M Gonzalez Vivo, M Urpí Ferreruela, B Castro Senosiain, I Pérez-Martínez, J Barrio, L Codesido Prado, B Caballol Oliva, V Pedrera Roman, M Piqueras Cano, F Rodríguez Moranta, M J Casanova González, L Ramos, M Iborra, C Tardillo Marin, M Barreiro-de Acosta, R H Lorente Poyatos, B Orts Jorquera, L Bujanda Fernández, Y Zabana, A López-García, S Riestra, P Vega-Villaamil, M Montoro, J P Gisbert, P Nos, G E Rodriguez Gonzalez, M Porto Silva, A Gutiérrez-Casbas, E Domenech, L Márquez
Publikováno v:
Journal of Crohn's and Colitis. 16:i208-i210
Background Patients with inflammatory bowel disease (IBD) are often classified as ulcerative colitis (UC) and Crohn’s disease (CD). However, in some cases this categorization is not possible and these patients are labelled as inflammatory bowel dis
Autor:
M Chaparro, A Gutiérrez, C Calviño-Suárez, J M Huguet, M Calvo, M Aguas, R Camargo Camero, M Á de Jorge Turrión, D Hervías Cruz, P López Serrano, S Marín Pedrosa, P Martínez Montiel, M Rivero, R Vicente Lidón, L Arias García, M Arroyo, L Bujanda, M J Casanova, M Figueiras, A J Lucendo, N Manceñido Marcos, L Márquez, M D Martín-Arranz, M Boscá Watts, Y Ber, P Ramírez de la Piscina Urraca, I Pérez-Martínez, V Robles, A Ruiz-Cerulla, J M Vázquez Morón, L Madero, M Barreiro-de Acosta, M Capilla, I Vera Mendoza, D Acosta, Y Brenes, S Hermida, P Parra, M G Donday, J P Gisbert
Publikováno v:
Journal of Crohn's and Colitis. 16:i491-i493
Background The safety of ustekinumab in pregnant patients with inflammatory bowel disease (IBD) and in their offspring has been barely studied. Aims Primary: To know the risk of serious adverse events (SAEs) in women exposed to ustekinumab during pre
Autor:
M J García, M Rivero, A Fernández-Clotet, R de Francisco, B Sicilia, F Mesonero, M L de Castro, M J Casanova, F Bertoletti, F J García Alonso, A López García, B Julián, X Calvet, M Barreiro-de Acosta, L Jara, P Varela, A Nuñez, E Ricart, S Riestra, L Arias, M Rodríguez, L Arranz, R Pajares, R Mena, M Calafat, P Camo, L Jiménez, A Ponferrada, R E Madrigal, J Llao, E Sesé, P Almela, L Codesido, S de la Maza, C Leal, E Sánchez, J R Pineda Mariño, E Domènech, M Chaparro, J P Gisbert
Publikováno v:
Journal of Crohn's and Colitis. 16:i121-i123
Background Main aim: To evaluate the retention rate of ustekinumab compared to vedolizumab in Crohn’s disease patients who failed anti-TNF therapy in clinical practice. Secondary aims: To compare the short-term and long-term effectiveness, and the